A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Part of paid clinical trials in Miami, Florida.
- Sponsor
- AstraZeneca
- Study ID
- NCT07064122
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Haematologic Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 110 Years
- Healthy Volunteers
- Not accepted
Interventions
- AZD2962 — DRUGAZD2962 will be administered orally once daily.
Study Details
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Key Dates
- Start date
- Nov 3, 2025
- Status verified
- Feb 2026
- Primary completion
- Oct 20, 2028
- Completion
- Oct 20, 2028
Study Design
- Enrollment
- 72 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Module 1- AZD2962 (Monotherapy)Participants with MDS and dysplastic CMML will receive AZD2962 as monotherapy in a dose escalation pattern.
Primary Outcome Measure
Number of participants with dose limiting toxicity (DLT) [ Time Frame: From Cycle 1 Day 1 up to end of Cycle 1 (28 Days) ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Miami | Florida | 33136 | - |
| Research Site | Tampa | Florida | 33612 | - |
| Research Site | Houston | Texas | 77030 | - |